Stocklytics Platform
Asset logo for symbol HOWL
Werewolf Therapeutics
HOWL67
$1.14arrow_drop_up2.70%$0.02
Penny Stock
Asset logo for symbol HOWL
HOWL67

$1.14

arrow_drop_up2.70%

Income Statement (HOWL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$17.12M-$16.10M-$15.19M-$10.76M-$9.69M
EBITDA-$16.67M-$15.65M-$14.72M-$10.30M-$9.25M
gross Profit-$689.00K$278.00K$1.04M$5.45M
NET Income-$16.67M-$17.24M-$16.19M-$12.00M-$8.28M
total Revenue$0.00$1.14M$742.00K$1.50M$5.89M

Balance Sheet (HOWL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$86.04M-$98.62M-$87.91M-$82.42M-$77.87M
stockholders Equity$89.37M$104.01M$117.58M$111.37M$112.44M
total Assets$140.03M$153.70M$177.60M$174.83M$176.38M
total Debt$36.77M$36.67M$51.27M$51.92M$52.18M
total Liabilities$50.65M$49.68M$60.01M$63.45M$2.40M

Cash Flow (HOWL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$6,000.00-$9.72M$20.25M$9.07M$41.00K
free Cash Flow-$12.46M-$14.19M-$15.40M-$4.78M-$7.42M
investing Cash Flow-----
operating Cash Flow-$12.46M-$14.17M-$15.29M-$4.58M-$7.20M

Werewolf Therapeutics (HOWL) Financials

The income statement of Werewolf Therapeutics, Inc. (HOWL) provides a comprehensive view of the company's financial performance. It showcases the revenues generated, expenses incurred, and net income derived from the stockholders' investments. The company's gross profit, which represents the revenue minus the cost of goods sold, offers insights into its operational efficiency and pricing strategy. Additionally, the EBIT (earnings before interest and taxes) and EBITDA (earnings before interest, taxes, depreciation, and amortization) allow investors to evaluate the company's profitability and cash flow generation capabilities.
Analyzing the balance sheet of Werewolf Therapeutics, Inc. (HOWL) reveals its financial position at a specific point in time. The total assets represent the company's resources, including cash equivalents, tangible and intangible assets, and investments. On the other hand, total liabilities encompass its debts and obligations. The stockholders' equity depicts the portion of the company's assets owned by the shareholders. By examining the net debt, investors can assess the company's leverage and its ability to meet its financial obligations.
Werewolf Therapeutics, Inc. (HOWL)'s cash flow statement sheds light on the sources and uses of its cash during a given period. It consists of three main sections: operating cash flow, investing cash flow, and financing cash flow. The operating cash flow demonstrates the company's ability to generate cash from its core operations, excluding any financing or investment activities. On the other hand, the investing cash flow represents the cash spent or received from purchasing or selling assets. Lastly, the financing cash flow accounts for the cash inflows or outflows from raising capital or repaying debts.
In summary, Werewolf Therapeutics, Inc. (HOWL) provides a comprehensive set of financial information through its income statement, balance sheet, and cash flow statement. These financial statements enable investors to assess the company's profitability, financial position, and cash flow generation. By analyzing key metrics such as total revenue, EBIT, EBITDA, and net income from stockholders, investors can make informed decisions regarding their investment in HOWL.
add Werewolf Therapeutics to watchlist

Keep an eye on Werewolf Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level